Israel

Cooley advised Gamida Cell Ltd. on its $50 million initial public offering of 6,250,000 shares of common stock. Partners Div Gupta, Daniel Goldberg and Josh Kaufman led the Cooley team advising Gamida Cell.

BMO Capital Markets and RBC Capital Markets acted as joint book-running managers for the offering. Needham & Company and Oppenheimer acted as co-lead managers.

Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company’s shares now trade on the Nasdaq Global Market under the symbol “GMDA.”

Cooley advised SeatGeek on its $57 million Series D financing round and concurrent acquisition of Israeli-based ticketing software company TopTix for $56 million.

Cooley advised Stratasys, a leading 3D printing solutions company, on its successful resolution of an Eighth Circuit appeal. In the decision, a three-judge panel affirmed the dismissal of a securities class action complaint asserting claims under the Securities and Exchange Act of 1934.

The lawsuit centered on Stratasys subsidiary MakerBot, a 3D printer manufacturer focused on consumer desktop 3D printing, and MakerBot’s release of its “fifth generation” or “5G” desktop 3D printers in 2014. Plaintiffs claimed that Stratasys’s public statements about the 5G printers were false or misleading.

The lawsuit was originally dismissed by Judge Patrick J. Schiltz of the US District Court for the District of Minnesota. The Eighth Circuit agreed with the lower court that the plaintiffs fell short of adequately pleading their claim.

Stratasys, which trades on the NASDAQ Global Select Market as “SSYS,” provides applied additive technology solutions for industries including aerospace, automotive, healthcare, consumer products and education. MakerBot was founded in 2009 and was one of the first companies to make 3D printing accessible and affordable.